Integración multimodal de datos cognitivos y morfométricos para el diagnóstico de la etapa de progresión de la enfermedad de Alzheimer

Sheyla  León Pino; Eduardo Garea Llano

Authors

Sheyla León Pino Cuban Neuroscience Center
Eduardo Garea Llano

Keywords:

Alzheimer’s disease, biomarkers, cognition, Artificial intelligence, magnetic resonance imaging

Abstract

This study addresses the early and accurate diagnosis of Alzheimer's disease, a key challenge in clinical neurology. We investigate an approach that combines morphometric biomarkers from magnetic resonance imaging with cognitive assessments, seeking to overcome the limitations of diagnostic methods that use these information sources in isolation. We analyzed data from 1,382 participants from the ADNI database, classified into cognitive controls, mild cognitive impairment (MCI), and Alzheimer's. We implemented machine learning algorithms, highlighting XGBoost with a balanced accuracy of 83.72%, superior to models based only on cognitive variables. The results indicate that multimodal integration improved the detection of MCI status, with an increase in sensitivity. The biomarkers with the greatest predictive power were hippocampal volumes, entorhinal cortex, and total gray matter measurements. This approach offers a more accurate diagnostic tool and aligns with the NIA-AA research framework, which emphasizes the biological definition of Alzheimer's through biomarkers. An earlier and more precise diagnosis would allow for more timely interventions and better selection of patients for clinical trials. This work demonstrates the potential of artificial intelligence to integrate different sources of information into a predictive model, with possible applications in clinical practice.

References

Alzheimer's Association. (2023). 2023 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 19(4), 1598-1695. https://doi.org/10.1002/alz.13016

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596

Barnes, D. E., Yaffe, K., Byers, A. L., McCormick, M., Schaefer, C., & Whitmer, R. A. (2009). Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Archives of General Psychiatry, 66(5), 527-533. https://doi.org/10.1001/archgenpsychiatry.2009.39

Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239-259. https://doi.org/10.1007/BF00308809

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., ... & Cummings, J. L. (2021). Revised criteria for diagnosis and staging of Alzheimer's disease. The Lancet Neurology, 20(6), 484-496. https://doi.org/10.1016/S1474-4422(21)00066-1

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., ... & Scheltens, P. (2016). Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. The Lancet Neurology, 13(6), 614-629. https://doi.org/10.1016/S1474-4422(14)70090-0

Falahati, F., Westman, E., & Simmons, A. (2014). Multimodal prediction of conversion to Alzheimer's disease in mild cognitive impairment. Journal of Alzheimer's Disease, 41(4), 1205-1219. https://doi.org/10.3233/JAD-140201

Fischl, B. (2012). FreeSurfer. NeuroImage, 62(2), 774-781. https://doi.org/10.1016/j.neuroimage.2012.01.021

Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 6(2), 67-77. https://doi.org/10.1038/nrneurol.2009.215

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B. ... & Sperling, R. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14(4), 535-562. https://doi.org/10.1016/j.jalz.2018.02.018

Jack, C. R., Petersen, R. C., O'Brien, P. C., & Tangalos, E. G. (1992). MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology, 42(1), 183-188. https://doi.org/10.1212/wnl.42.1.183

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., ... & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005

Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O. ... & Duchesnay, E. (2011). Scikit-learn: Machine learning in Python. Journal of Machine Learning Research, 12, 2825–2830. http://www.jmlr.org/papers/v12/pedregosa11a.html

Risacher, S. L., Saykin, A. J., West, J. D., Shen, L., Firpi, H. A., & McDonald, B. C. (2019). MRI biomarkers in Alzheimer's disease. NeuroImage: Clinical, 22, 101771. https://doi.org/10.1016/j.nicl.2019.101771

Thompson, P. M., et al. (2017). The Alzheimer's Disease Neuroimaging Initiative: Progress and innovation. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 1-8. https://doi.org/10.1016/j.dadm.2017.02.001

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., ... & Trojanowski, J. Q. (2013). The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's & Dementia, 9(5), e111-e194. https://doi.org/10.1016/j.jalz.2013.05.1769

World Health Organization. (2022). Global action plan on the public health response to dementia 2017-2025. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025